Research programme: nanoparticle therapeutics - Cristal Therapeutics

Drug Profile

Research programme: nanoparticle therapeutics - Cristal Therapeutics

Alternative Names: CriPec Actively Targeted Nanoparticles - Cristal Therapeutics; CriPec ATN - Cristal Therapeutics; CriPec oligonucleotides - Cristal Therapeutics; CriPec® DUO; CriPec® dexamethasone; CriPec® DUO - Cristal Therapeutics; CriPec® peptides - Cristal Therapeutics; Dexamethasone nanoparticle - Cristal therapeutics; Exenatide nanoparticle - Cristal Therapeutics; Leuprolide nanoparticle - Cristal Therapeutics; Octreotide nanoparticle - Cristal Therapeutics

Latest Information Update: 27 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cristal Therapeutics
  • Class Fluorinated steroids; Glucocorticoids; Peptides; Pregnadienetriols
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammation; Solid tumours

Most Recent Events

  • 27 Jan 2016 Research programme: nanoparticle therapeutics - Cristal Therapeutics is available for licensing as of 27 Jan 2016.
  • 27 Jan 2016 Cristal Therapeutics has patent protection for drug delivery systems prepared using CriPec Technology (Cristal Therapeutics website, January 2016)
  • 25 Jan 2016 Early research in Solid tumours in Netherlands (IV) prior to January 2016 (Cristal Therapeutics pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top